How to Revive Breakthrough Innovation in the Pharmaceutical Industry
- 29 June 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (89) , 89cm16
Abstract
Pharmaceutical firms must reengage in high-risk discovery research and only take genuine breakthroughs to the clinic.Keywords
This publication has 12 references indexed in Scilit:
- Leveraging Crowdsourcing to Facilitate the Discovery of New MedicinesScience Translational Medicine, 2011
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Open access consortiumNature Biotechnology, 2011
- The Precompetitive Space: Time to Move the YardsticksScience Translational Medicine, 2011
- Phase III and submission failures: 2007–2010Nature Reviews Drug Discovery, 2011
- A Call for Sharing: Adapting Pharmaceutical Research to New RealitiesScience Translational Medicine, 2009
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Managing technological transitions through R&D alliancesR&D Management, 2009
- Portfolio analysis and R&D decision makingNature Reviews Drug Discovery, 2009
- Technology policy for a world of skew-distributed outcomesResearch Policy, 2000